Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Patients with kidney failure on hemodialysis (HD) experience considerable symptom burden and poor health-related quality of life (HRQoL). There is limited use of patient reported outcome measures (PROMs) in facility HD units to direct immediate care, with response rates in other studies between 36 to 70%. The aim of this pilot study was to evaluate feasibility of electronic PROMs (e-PROMs) in HD participants, with feedback 3-monthly to the participants' treating team, for severe or worsening symptoms as identified by the Integrated Palliative Outcome Scale (IPOS-Renal), with linkage to the Australian and New Zealand Dialysis and Transplant (ANZDATA) registry, compared with usual care.
Methods: This is a registry-based cluster-randomized controlled pilot trial involving all adults receiving HD in 4 satellite units in Australia over a 6-month period. HD units were cluster randomized 1:1 to the control (HRQoL data collection only) or intervention arm (symptom monitoring with feedback to treating team every 3 months). Feasibility was assessed by participant response rate (percentage of eligible HD participants, including new incident participants, who completed the questionnaire at each time point); retention rate (percentage of participants who completed the baseline questionnaire and all subsequent measures); and completion time. HRQoL and symptom burden scores are described.
Results: There were 226 unique participants who completed the e-PROMs (mean age 62 years, 69% males, 78% White-European, median dialysis vintage 1.62 years). At 6 months, response rate and retention rate for the intervention arm were 54% and 68%, respectively, and 89% and 97% in the control arm. Median time to complete IPOS-Renal was 6.6 min (5.3, 10.1) at 3 months, and when combined with the outcome measure (EQ-5D-5L), the median time was 9.4 min (6.9, 13.6) at 6 months.
Conclusions: Electronic symptom monitoring among HD participants with feedback to clinicians is feasible. Variations in response and retention rates could be potentially explained by the lengthier questionnaire, and higher frequency of data collection time points for participants in the intervention arm. A definitive national RCT is underway.
Trial Registration: ACTRN12618001976279 (07/12/2018).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666372 | PMC |
| http://dx.doi.org/10.1186/s12882-023-03399-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanically Heterogeneous Architecture Enables Robust and Ultrathin Bioelectronics for High-Fidelity Biosignal Monitoring.
ACS Sens
September 2025
State Key Laboratory of Advanced Fiber Materials, College of Materials Science and Engineering, Donghua University, Shanghai 201620, China.
High-fidelity biosignal monitoring is essential for daily health tracking and the diagnosis of chronic diseases. However, developing bioelectrodes capable of withstanding repeated use and mechanical deformation on wet tissue surfaces remains a significant challenge. Here, we present a robust and ultrathin bioelectrode (RUB), featuring a mechanically heterogeneous architecture and a thickness of ∼3 μm.
View Article and Find Full Text PDFEtripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study.
J Cardiovasc Electrophysiol
September 2025
City St George's University of London, London, UK.
Introduction: Etripamil is a fast-acting intranasally self-administered calcium-channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE-303 is an open-label, single-arm study that evaluated etripamil for multiple, at-home PSVT episodes, without test dose before first use.
View Article and Find Full Text PDFAn Association Analysis of Anxiety and Psoriasis: Based on the NHANES Database.
Brain Behav
September 2025
Department of Dermatology, Yulin First Hospital, Yulin, Shaanxi Province, China.
Background: Psoriasis is linked with an elevated risk of anxiety disorders, and there may be a temporal relationship between the two. However, the association between anxiety status and its duration with psoriasis is unclear.
Objectives: The present work aimed to figure out the association between anxiety and the risk of psoriasis.
Introduction: Injectable extended-release buprenorphine is an effective treatment for opioid use disorder (OUD), but injection site reactions (ISRs) are common treatment-emergent adverse events that may impact patient comfort, adherence, and outcome. This report examines the clinical presentation, prevalence, and management of Sublocade-related ISRs through two case studies and a review of existing literature.
Case Presentation: We present two cases of ISRs in patients receiving extended-release buprenorphine, Sublocade.
Hormonal Contraceptives and Depression: A Proteomic Analysis Using Neuronal Models.
Proteomics Clin Appl
September 2025
Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany.
Purpose: Hormonal contraceptives are linked to a higher prevalence of depressive symptoms. Given their popularity in Western countries, understanding the biochemical effects on neuronal cells is crucial to minimizing mental health risks.
Experimental Design: Neural progenitor cells were treated with ethinyl estradiol (EE) and levonorgestrel (LNG), two synthetic sex hormones commonly used in oral contraception, and S-23, a selective androgen receptor modulator developed as a potential synthetic sex hormone for male hormonal contraception.